Extended release formulation and method of treating adrenergic dysregulation
US7884122B2 · kind B2 · utility
2Cited by
72References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Nov 10, 2009 |
| Grant date | Feb 8, 2011 |
| Priority date | — |
| Expiry date | Nov 10, 2029 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P43/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A composition and method of treating adrenergic dysregulation by administering the composition is disclosed, wherein the composition comprises a a2-adrenergic receptor agonist; a pharmaceutically acceptable hydrophilic matrix and a release-retardant of a metal alkyl sulfate. In embodiments, the composition provides a sustained release of the agonist, wherein after administration of the composition no more than once about every 12 hours to a subject having a steady state plasma concentration of the a2-adrenergic receptor agonist, the agonist's plasma concentration peak-to-trough ratio is no greater than about 1.9.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.